The	O
effects	O
of	O
probiotic	B:C0525033
and	O
synbiotic	O
supplementation	O
on	O
metabolic	O
syndrome	I:C0524620
indices	O
in	O
adults	O
at	O
risk	O
of	O
type	O
2	I:C0011860
diabetes	I:C0011860
:	O
study	O
protocol	I:C1507394
for	O
a	O
randomized	O
controlled	I:C0206035
trial	I:C0206035

The	O
effects	O
of	O
probiotic	O
and	O
synbiotic	B:C2936470
supplementation	O
on	O
metabolic	O
syndrome	I:C0524620
indices	O
in	O
adults	O
at	O
risk	O
of	O
type	O
2	I:C0011860
diabetes	I:C0011860
:	O
study	O
protocol	I:C1507394
for	O
a	O
randomized	O
controlled	I:C0206035
trial	I:C0206035

The	O
effects	O
of	O
probiotic	O
and	O
synbiotic	O
supplementation	B:C0242296
on	O
metabolic	O
syndrome	I:C0524620
indices	O
in	O
adults	O
at	O
risk	O
of	O
type	O
2	I:C0011860
diabetes	I:C0011860
:	O
study	O
protocol	I:C1507394
for	O
a	O
randomized	O
controlled	I:C0206035
trial	I:C0206035

The	O
effects	O
of	O
probiotic	O
and	O
synbiotic	O
supplementation	O
on	O
metabolic	B:C0524620
syndrome	I:C0524620
indices	O
in	O
adults	O
at	O
risk	O
of	O
type	O
2	I:C0011860
diabetes	I:C0011860
:	O
study	O
protocol	I:C1507394
for	O
a	O
randomized	O
controlled	I:C0206035
trial	I:C0206035

The	O
effects	O
of	O
probiotic	O
and	O
synbiotic	O
supplementation	O
on	O
metabolic	O
syndrome	I:C0524620
indices	O
in	O
adults	O
at	O
risk	O
of	O
type	B:C0011860
2	I:C0011860
diabetes	I:C0011860
:	O
study	O
protocol	I:C1507394
for	O
a	O
randomized	O
controlled	I:C0206035
trial	I:C0206035

The	O
effects	O
of	O
probiotic	O
and	O
synbiotic	O
supplementation	O
on	O
metabolic	O
syndrome	I:C0524620
indices	O
in	O
adults	O
at	O
risk	O
of	O
type	O
2	I:C0011860
diabetes	I:C0011860
:	O
study	B:C1507394
protocol	I:C1507394
for	O
a	O
randomized	O
controlled	I:C0206035
trial	I:C0206035

The	O
effects	O
of	O
probiotic	O
and	O
synbiotic	O
supplementation	O
on	O
metabolic	O
syndrome	I:C0524620
indices	O
in	O
adults	O
at	O
risk	O
of	O
type	O
2	I:C0011860
diabetes	I:C0011860
:	O
study	O
protocol	I:C1507394
for	O
a	O
randomized	B:C0206035
controlled	I:C0206035
trial	I:C0206035

The	O
incidence	O
of	O
type	B:C0011860
2	I:C0011860
diabetes	I:C0011860
,	O
cardiovascular	O
diseases	I:C0007222
,	O
and	O
obesity	O
has	O
been	O
rising	O
dramatically	O
;	O
however	O
,	O
their	O
pathogenesis	O
is	O
particularly	O
intriguing	O
.	O

The	O
incidence	O
of	O
type	O
2	I:C0011860
diabetes	I:C0011860
,	O
cardiovascular	B:C0007222
diseases	I:C0007222
,	O
and	O
obesity	O
has	O
been	O
rising	O
dramatically	O
;	O
however	O
,	O
their	O
pathogenesis	O
is	O
particularly	O
intriguing	O
.	O

The	O
incidence	O
of	O
type	O
2	I:C0011860
diabetes	I:C0011860
,	O
cardiovascular	O
diseases	I:C0007222
,	O
and	O
obesity	B:C0028754
has	O
been	O
rising	O
dramatically	O
;	O
however	O
,	O
their	O
pathogenesis	O
is	O
particularly	O
intriguing	O
.	O

The	O
incidence	O
of	O
type	O
2	I:C0011860
diabetes	I:C0011860
,	O
cardiovascular	O
diseases	I:C0007222
,	O
and	O
obesity	O
has	O
been	O
rising	O
dramatically	O
;	O
however	O
,	O
their	O
pathogenesis	B:C0699748
is	O
particularly	O
intriguing	O
.	O

The	O
incidence	O
of	O
type	O
2	I:C0011860
diabetes	I:C0011860
,	O
cardiovascular	O
diseases	I:C0007222
,	O
and	O
obesity	O
has	O
been	O
rising	O
dramatically	O
;	O
however	O
,	O
their	O
pathogenesis	O
is	O
particularly	O
intriguing	B:C0543488
.	O

Recently	O
,	O
dysbiosis	B:C3658208
of	O
the	O
intestinal	O
microbiota	O
has	O
emerged	O
as	O
a	O
new	O
candidate	O
that	O
may	O
be	O
linked	O
to	O
metabolic	O
diseases	I:C0025517
.	O

Recently	O
,	O
dysbiosis	O
of	O
the	O
intestinal	O
microbiota	O
has	O
emerged	O
as	O
a	O
new	O
candidate	O
that	O
may	O
be	O
linked	O
to	O
metabolic	B:C0025517
diseases	I:C0025517
.	O

We	O
hypothesize	O
that	O
selective	O
modulation	O
of	O
the	O
intestinal	O
microbiota	O
by	O
probiotic	B:C0525033
or	O
synbiotic	O
supplementation	O
may	O
improve	O
metabolic	O
dysfunction	I:C0025517
and	O
prevent	O
diabetes	O
in	O
prediabetics	O
.	O

We	O
hypothesize	O
that	O
selective	O
modulation	O
of	O
the	O
intestinal	O
microbiota	O
by	O
probiotic	O
or	O
synbiotic	B:C2936470
supplementation	O
may	O
improve	O
metabolic	O
dysfunction	I:C0025517
and	O
prevent	O
diabetes	O
in	O
prediabetics	O
.	O

We	O
hypothesize	O
that	O
selective	O
modulation	O
of	O
the	O
intestinal	O
microbiota	O
by	O
probiotic	O
or	O
synbiotic	O
supplementation	B:C0242296
may	O
improve	O
metabolic	O
dysfunction	I:C0025517
and	O
prevent	O
diabetes	O
in	O
prediabetics	O
.	O

We	O
hypothesize	O
that	O
selective	O
modulation	O
of	O
the	O
intestinal	O
microbiota	O
by	O
probiotic	O
or	O
synbiotic	O
supplementation	O
may	O
improve	O
metabolic	B:C0025517
dysfunction	I:C0025517
and	O
prevent	O
diabetes	O
in	O
prediabetics	O
.	O

We	O
hypothesize	O
that	O
selective	O
modulation	O
of	O
the	O
intestinal	O
microbiota	O
by	O
probiotic	O
or	O
synbiotic	O
supplementation	O
may	O
improve	O
metabolic	O
dysfunction	I:C0025517
and	O
prevent	O
diabetes	B:C0011847
in	O
prediabetics	O
.	O

We	O
hypothesize	O
that	O
selective	O
modulation	O
of	O
the	O
intestinal	O
microbiota	O
by	O
probiotic	O
or	O
synbiotic	O
supplementation	O
may	O
improve	O
metabolic	O
dysfunction	I:C0025517
and	O
prevent	O
diabetes	O
in	O
prediabetics	B:C0362046
.	O

In	O
this	O
study	B:C2603343
,	O
a	O
synthesis	O
and	O
study	O
of	O
synbiotics	O
will	O
be	O
carried	O
out	O
for	O
the	O
first	O
time	O
in	O
Iran	O
.	O

In	O
this	O
study	O
,	O
a	O
synthesis	O
and	O
study	B:C2603343
of	O
synbiotics	O
will	O
be	O
carried	O
out	O
for	O
the	O
first	O
time	O
in	O
Iran	O
.	O

In	O
this	O
study	O
,	O
a	O
synthesis	O
and	O
study	O
of	O
synbiotics	B:C2936470
will	O
be	O
carried	O
out	O
for	O
the	O
first	O
time	O
in	O
Iran	O
.	O

In	O
this	O
study	O
,	O
a	O
synthesis	O
and	O
study	O
of	O
synbiotics	O
will	O
be	O
carried	O
out	O
for	O
the	O
first	O
time	O
in	O
Iran	B:C0022065
.	O

In	O
a	O
randomized	B:C0206035
triple	I:C0206035
-	I:C0206035
blind	I:C0206035
controlled	I:C0206035
clinical	I:C0206035
trial	I:C0206035
,	O
120	O
adults	O
with	O
impaired	O
glucose	I:C0271650
tolerance	I:C0271650
based	O
on	O
the	O
inclusion	O
criteria	O
will	O
be	O
selected	O
by	O
a	O
simple	O
random	O
sampling	O
method	I:C0449370
and	O
will	O
be	O
randomly	O
allocated	O
to	O
6	O
months	O
of	O
6	O
g/d	O
probiotic	O
,	O
synbiotic	O
or	O
placebo	O
.	O

In	O
a	O
randomized	O
triple	I:C0206035
-	I:C0206035
blind	I:C0206035
controlled	I:C0206035
clinical	I:C0206035
trial	I:C0206035
,	O
120	O
adults	O
with	O
impaired	B:C0271650
glucose	I:C0271650
tolerance	I:C0271650
based	O
on	O
the	O
inclusion	O
criteria	O
will	O
be	O
selected	O
by	O
a	O
simple	O
random	O
sampling	O
method	I:C0449370
and	O
will	O
be	O
randomly	O
allocated	O
to	O
6	O
months	O
of	O
6	O
g/d	O
probiotic	O
,	O
synbiotic	O
or	O
placebo	O
.	O

In	O
a	O
randomized	O
triple	I:C0206035
-	I:C0206035
blind	I:C0206035
controlled	I:C0206035
clinical	I:C0206035
trial	I:C0206035
,	O
120	O
adults	O
with	O
impaired	O
glucose	I:C0271650
tolerance	I:C0271650
based	O
on	O
the	O
inclusion	O
criteria	O
will	O
be	O
selected	O
by	O
a	O
simple	O
random	O
sampling	B:C0449370
method	I:C0449370
and	O
will	O
be	O
randomly	O
allocated	O
to	O
6	O
months	O
of	O
6	O
g/d	O
probiotic	O
,	O
synbiotic	O
or	O
placebo	O
.	O

In	O
a	O
randomized	O
triple	I:C0206035
-	I:C0206035
blind	I:C0206035
controlled	I:C0206035
clinical	I:C0206035
trial	I:C0206035
,	O
120	O
adults	O
with	O
impaired	O
glucose	I:C0271650
tolerance	I:C0271650
based	O
on	O
the	O
inclusion	O
criteria	O
will	O
be	O
selected	O
by	O
a	O
simple	O
random	O
sampling	O
method	I:C0449370
and	O
will	O
be	O
randomly	O
allocated	O
to	O
6	O
months	O
of	O
6	O
g/d	O
probiotic	B:C0525033
,	O
synbiotic	O
or	O
placebo	O
.	O

In	O
a	O
randomized	O
triple	I:C0206035
-	I:C0206035
blind	I:C0206035
controlled	I:C0206035
clinical	I:C0206035
trial	I:C0206035
,	O
120	O
adults	O
with	O
impaired	O
glucose	I:C0271650
tolerance	I:C0271650
based	O
on	O
the	O
inclusion	O
criteria	O
will	O
be	O
selected	O
by	O
a	O
simple	O
random	O
sampling	O
method	I:C0449370
and	O
will	O
be	O
randomly	O
allocated	O
to	O
6	O
months	O
of	O
6	O
g/d	O
probiotic	O
,	O
synbiotic	B:C2936470
or	O
placebo	O
.	O

In	O
a	O
randomized	O
triple	I:C0206035
-	I:C0206035
blind	I:C0206035
controlled	I:C0206035
clinical	I:C0206035
trial	I:C0206035
,	O
120	O
adults	O
with	O
impaired	O
glucose	I:C0271650
tolerance	I:C0271650
based	O
on	O
the	O
inclusion	O
criteria	O
will	O
be	O
selected	O
by	O
a	O
simple	O
random	O
sampling	O
method	I:C0449370
and	O
will	O
be	O
randomly	O
allocated	O
to	O
6	O
months	O
of	O
6	O
g/d	O
probiotic	O
,	O
synbiotic	O
or	O
placebo	B:C1696465
.	O

The	O
fecal	B:C0015733
abundance	O
of	O
bacteria	O
,	O
blood	O
pressure	I:C0005823
,	O
height	O
,	O
weight	O
,	O
and	O
waist	O
and	O
hip	O
circumferences	I:C0562350
will	O
be	O
measured	O
at	O
baseline	O
and	O
following	O
treatment	O
.	O

The	O
fecal	O
abundance	O
of	O
bacteria	B:C0004611
,	O
blood	O
pressure	I:C0005823
,	O
height	O
,	O
weight	O
,	O
and	O
waist	O
and	O
hip	O
circumferences	I:C0562350
will	O
be	O
measured	O
at	O
baseline	O
and	O
following	O
treatment	O
.	O

The	O
fecal	O
abundance	O
of	O
bacteria	O
,	O
blood	B:C0005823
pressure	I:C0005823
,	O
height	O
,	O
weight	O
,	O
and	O
waist	O
and	O
hip	O
circumferences	I:C0562350
will	O
be	O
measured	O
at	O
baseline	O
and	O
following	O
treatment	O
.	O

The	O
fecal	O
abundance	O
of	O
bacteria	O
,	O
blood	O
pressure	I:C0005823
,	O
height	O
,	O
weight	O
,	O
and	O
waist	B:C0455829
and	O
hip	O
circumferences	I:C0562350
will	O
be	O
measured	O
at	O
baseline	O
and	O
following	O
treatment	O
.	O

The	O
fecal	O
abundance	O
of	O
bacteria	O
,	O
blood	O
pressure	I:C0005823
,	O
height	O
,	O
weight	O
,	O
and	O
waist	O
and	O
hip	B:C0562350
circumferences	I:C0562350
will	O
be	O
measured	O
at	O
baseline	O
and	O
following	O
treatment	O
.	O

The	O
fecal	O
abundance	O
of	O
bacteria	O
,	O
blood	O
pressure	I:C0005823
,	O
height	O
,	O
weight	O
,	O
and	O
waist	O
and	O
hip	O
circumferences	I:C0562350
will	O
be	O
measured	O
at	O
baseline	O
and	O
following	O
treatment	B:C0087111
.	O

Also	O
,	O
plasma	O
lipid	O
profiles	O
,	O
HbA1C	B:C0019018
,	O
fasting	O
plasma	I:C0583513
glucose	I:C0583513
,	O
and	O
insulin	O
levels	O
,	O
will	O
be	O
measured	O
and	O
insulin	O
resistance	I:C4049994
(	O
HOMA	O
-	I:C4049994
IR	I:C4049994
)	O
and	O
beta-cell	O
function	I:C4055385
(	O
HOMA	O
-	I:C4055385
B	I:C4055385
)	O
will	O
be	O
calculated	O
at	O
baseline	O
and	O
will	O
be	O
repeated	O
at	O
months	O
3	O
,	O
6	O
,	O
12	O
,	O
and	O
18	O
.	O

Also	O
,	O
plasma	O
lipid	O
profiles	O
,	O
HbA1C	O
,	O
fasting	B:C0583513
plasma	I:C0583513
glucose	I:C0583513
,	O
and	O
insulin	O
levels	O
,	O
will	O
be	O
measured	O
and	O
insulin	O
resistance	I:C4049994
(	O
HOMA	O
-	I:C4049994
IR	I:C4049994
)	O
and	O
beta-cell	O
function	I:C4055385
(	O
HOMA	O
-	I:C4055385
B	I:C4055385
)	O
will	O
be	O
calculated	O
at	O
baseline	O
and	O
will	O
be	O
repeated	O
at	O
months	O
3	O
,	O
6	O
,	O
12	O
,	O
and	O
18	O
.	O

Also	O
,	O
plasma	O
lipid	O
profiles	O
,	O
HbA1C	O
,	O
fasting	O
plasma	I:C0583513
glucose	I:C0583513
,	O
and	O
insulin	B:C0021641
levels	O
,	O
will	O
be	O
measured	O
and	O
insulin	O
resistance	I:C4049994
(	O
HOMA	O
-	I:C4049994
IR	I:C4049994
)	O
and	O
beta-cell	O
function	I:C4055385
(	O
HOMA	O
-	I:C4055385
B	I:C4055385
)	O
will	O
be	O
calculated	O
at	O
baseline	O
and	O
will	O
be	O
repeated	O
at	O
months	O
3	O
,	O
6	O
,	O
12	O
,	O
and	O
18	O
.	O

Also	O
,	O
plasma	O
lipid	O
profiles	O
,	O
HbA1C	O
,	O
fasting	O
plasma	I:C0583513
glucose	I:C0583513
,	O
and	O
insulin	O
levels	O
,	O
will	O
be	O
measured	O
and	O
insulin	B:C4049994
resistance	I:C4049994
(	O
HOMA	O
-	I:C4049994
IR	I:C4049994
)	O
and	O
beta-cell	O
function	I:C4055385
(	O
HOMA	O
-	I:C4055385
B	I:C4055385
)	O
will	O
be	O
calculated	O
at	O
baseline	O
and	O
will	O
be	O
repeated	O
at	O
months	O
3	O
,	O
6	O
,	O
12	O
,	O
and	O
18	O
.	O

Also	O
,	O
plasma	O
lipid	O
profiles	O
,	O
HbA1C	O
,	O
fasting	O
plasma	I:C0583513
glucose	I:C0583513
,	O
and	O
insulin	O
levels	O
,	O
will	O
be	O
measured	O
and	O
insulin	O
resistance	I:C4049994
(	O
HOMA	B:C4049994
-	I:C4049994
IR	I:C4049994
)	O
and	O
beta-cell	O
function	I:C4055385
(	O
HOMA	O
-	I:C4055385
B	I:C4055385
)	O
will	O
be	O
calculated	O
at	O
baseline	O
and	O
will	O
be	O
repeated	O
at	O
months	O
3	O
,	O
6	O
,	O
12	O
,	O
and	O
18	O
.	O

Also	O
,	O
plasma	O
lipid	O
profiles	O
,	O
HbA1C	O
,	O
fasting	O
plasma	I:C0583513
glucose	I:C0583513
,	O
and	O
insulin	O
levels	O
,	O
will	O
be	O
measured	O
and	O
insulin	O
resistance	I:C4049994
(	O
HOMA	O
-	I:C4049994
IR	I:C4049994
)	O
and	O
beta-cell	B:C4055385
function	I:C4055385
(	O
HOMA	O
-	I:C4055385
B	I:C4055385
)	O
will	O
be	O
calculated	O
at	O
baseline	O
and	O
will	O
be	O
repeated	O
at	O
months	O
3	O
,	O
6	O
,	O
12	O
,	O
and	O
18	O
.	O

Also	O
,	O
plasma	O
lipid	O
profiles	O
,	O
HbA1C	O
,	O
fasting	O
plasma	I:C0583513
glucose	I:C0583513
,	O
and	O
insulin	O
levels	O
,	O
will	O
be	O
measured	O
and	O
insulin	O
resistance	I:C4049994
(	O
HOMA	O
-	I:C4049994
IR	I:C4049994
)	O
and	O
beta-cell	O
function	I:C4055385
(	O
HOMA	B:C4055385
-	I:C4055385
B	I:C4055385
)	O
will	O
be	O
calculated	O
at	O
baseline	O
and	O
will	O
be	O
repeated	O
at	O
months	O
3	O
,	O
6	O
,	O
12	O
,	O
and	O
18	O
.	O

The	O
data	O
will	O
be	O
compared	O
within	O
and	O
between	O
groups	O
using	O
statistical	B:C1710191
methods	I:C1710191
.	O

The	O
results	O
of	O
this	O
trial	B:C0206035
could	O
contribute	O
to	O
the	O
evidence	O
-	I:C0282451
based	I:C0282451
clinical	I:C0282451
guidelines	I:C0282451
that	O
address	O
gut	O
microbiota	O
manipulation	O
to	O
maximize	O
health	O
benefits	O
in	O
prevention	O
and	O
management	O
of	O
metabolic	O
syndrome	I:C0524620
in	O
prediabetes	O
.	O

The	O
results	O
of	O
this	O
trial	O
could	O
contribute	O
to	O
the	O
evidence	B:C0282451
-	I:C0282451
based	I:C0282451
clinical	I:C0282451
guidelines	I:C0282451
that	O
address	O
gut	O
microbiota	O
manipulation	O
to	O
maximize	O
health	O
benefits	O
in	O
prevention	O
and	O
management	O
of	O
metabolic	O
syndrome	I:C0524620
in	O
prediabetes	O
.	O

The	O
results	O
of	O
this	O
trial	O
could	O
contribute	O
to	O
the	O
evidence	O
-	I:C0282451
based	I:C0282451
clinical	I:C0282451
guidelines	I:C0282451
that	O
address	O
gut	O
microbiota	O
manipulation	B:C0087111
to	O
maximize	O
health	O
benefits	O
in	O
prevention	O
and	O
management	O
of	O
metabolic	O
syndrome	I:C0524620
in	O
prediabetes	O
.	O

The	O
results	O
of	O
this	O
trial	O
could	O
contribute	O
to	O
the	O
evidence	O
-	I:C0282451
based	I:C0282451
clinical	I:C0282451
guidelines	I:C0282451
that	O
address	O
gut	O
microbiota	O
manipulation	O
to	O
maximize	O
health	O
benefits	O
in	O
prevention	B:C0199176
and	O
management	O
of	O
metabolic	O
syndrome	I:C0524620
in	O
prediabetes	O
.	O

The	O
results	O
of	O
this	O
trial	O
could	O
contribute	O
to	O
the	O
evidence	O
-	I:C0282451
based	I:C0282451
clinical	I:C0282451
guidelines	I:C0282451
that	O
address	O
gut	O
microbiota	O
manipulation	O
to	O
maximize	O
health	O
benefits	O
in	O
prevention	O
and	O
management	B:C0376636
of	O
metabolic	O
syndrome	I:C0524620
in	O
prediabetes	O
.	O

The	O
results	O
of	O
this	O
trial	O
could	O
contribute	O
to	O
the	O
evidence	O
-	I:C0282451
based	I:C0282451
clinical	I:C0282451
guidelines	I:C0282451
that	O
address	O
gut	O
microbiota	O
manipulation	O
to	O
maximize	O
health	O
benefits	O
in	O
prevention	O
and	O
management	O
of	O
metabolic	B:C0524620
syndrome	I:C0524620
in	O
prediabetes	O
.	O

The	O
results	O
of	O
this	O
trial	O
could	O
contribute	O
to	O
the	O
evidence	O
-	I:C0282451
based	I:C0282451
clinical	I:C0282451
guidelines	I:C0282451
that	O
address	O
gut	O
microbiota	O
manipulation	O
to	O
maximize	O
health	O
benefits	O
in	O
prevention	O
and	O
management	O
of	O
metabolic	O
syndrome	I:C0524620
in	O
prediabetes	B:C0362046
.	O

Iranian	B:C0034975
Registry	I:C0034975
of	O
Clinical	O
Trials	I:C0008976
:	O
IRCT201511032321N2	O
.	O

Iranian	O
Registry	I:C0034975
of	O
Clinical	B:C0008976
Trials	I:C0008976
:	O
IRCT201511032321N2	O
.	O

Iranian	O
Registry	I:C0034975
of	O
Clinical	O
Trials	I:C0008976
:	O
IRCT201511032321N2	B:C0282574
.	O

